Plasma urate and risk of a hospital stay with AKI: The atherosclerosis risk in communities study

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 5, 2015, Pages 776-783

  Greenberg, Keiko I ^a   McAdams Demarco, Mara A ^a,b   Köttgen, Anna ^b,c   Appel, Lawrence J ^a,b,d   Coresh, Josef ^b,d   Grams, Morgan E ^a,b,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; URIC ACID;

ADULT; ARTICLE; ATHEROSCLEROSIS; FEMALE; FOLLOW UP; GENOTYPING TECHNIQUE; GLOMERULUS FILTRATION RATE; GOUT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY ANALYSIS; URIC ACID BLOOD LEVEL; ACUTE KIDNEY INJURY; AGED; BLOOD; GENETICS; MENDELIAN RANDOMIZATION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACUTE KIDNEY INJURY; AGED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GOUT; HOSPITALIZATION; HUMANS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES; URIC ACID;

EID: 84929206985     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05870614     Document Type: Article

References (41)

1. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R: Acute kidney injury: An increasing global concern. Lancet 382: 170–179, 2013
2. Waikar SS, Liu KD, Chertow GM: Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 3: 844–861, 2008
3. Leung KC, Tonelli M, James MT: Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 9: 77–85, 2013
4. Kidney Disease:Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int 2(Suppl): 1–138, 2012
5. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord SD: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61: 649–672, 2013
6. Jalal DI, Chonchol M, Chen W, Targher G: Uric acid as a target of therapy in CKD. Am J Kidney Dis 61: 134–146, 2013
7. Ben-Dov IZ, Kark JD: Serumuric acid is a GFR-independent longterm predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant 26: 2558–2566, 2011
8. Ejaz AA, Beaver TM, Shimada M, Sood P, Lingegowda V, Schold JD, Kim T, Johnson RJ: Uric acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients? Am J Nephrol 30: 425–429, 2009
9. Lapsia V, Johnson RJ, Dass B, Shimada M, Kambhampati G, Ejaz NI, Arif AA, Ejaz AA: Elevated uric acid increases the risk for acute kidney injury. Am J Med 125: e9–e17, 2012
10. Ejaz AA, Kambhampati G, Ejaz NI, Dass B, Lapsia V, Arif AA, Asmar A, Shimada M, Alsabbagh MM, Aiyer R, Johnson RJ: Postoperative serum uric acid and acute kidney injury. J Nephrol 25: 497–505, 2012
11. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 129: 687–702, 1989
12. Juraschek SP, McAdams-Demarco M, Miller ER, Gelber AC, Maynard JW, Pankow JS, Young H, Coresh J, Selvin E: Temporal relationship between uric acid concentration and risk of diabetes in a community-based study population. Am J Epidemiol 179: 684–691, 2014
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009
14. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M: Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 19: 1855–1860, 2001
15. McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 38: 135–141, 2011
16. DeMarco MA, Maynard JW, Huizinga MM, Baer AN, Kottgen A, Gelber AC, Coresh J: Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res (Hoboken) 63: 1108–1114, 2011
17. Maynard JW, McAdams DeMarco MA, Baer AN, Kottgen A, Folsom AR, Coresh J, Gelber AC: Incident gout in women and association with obesity in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Med 125: e9, e17, 2012
18. Maynard JW, McAdams-Demarco MA, Law A, Kao L, Gelber AC, Coresh J, Baer AN: Racial differences in gout incidence in a population-based cohort: Atherosclerosis Risk in Communities study. Am J Epidemiol 179: 576–583, 2014
19. McAdams-DeMarco MA, Maynard JW, Baer AN, Coresh J: Hypertension and the risk of incident gout in a population-based study: The Atherosclerosis Risk in Communities cohort. J Clin Hypertens (Greenwich) 14: 675–679, 2012
20. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, Coresh J: Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 64: 121–129, 2012
21. McAdams-Demarco MA, Maynard JW, Baer AN, Kao LW, Kottgen A, Coresh J: A urate gene-by-diuretic interaction and gout risk in participants with hypertension: Results from the ARIC study. Ann Rheum Dis 72: 701–706, 2013
22. McAdams-DeMarco MA, Maynard JW, Coresh J, Baer AN: Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study. Arthritis Res Ther 14: R193, 2012
23. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G: Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med 27: 1133–1163, 2008
24. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Linda Kao WH, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larson MG, O’Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, Rivadeneira F, Stricker B, Uitterlinden AG, Pare G, Parker AN, Ridker PM, Siscovick DS, Gudnason V, Witteman JC, Fox CS, Coresh J: Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3: 523–530, 2010
25. Grams ME, Astor BC, Bash LD, Matsushita K, Wang Y, Coresh J: Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol 21: 1757–1764, 2010
26. Grams ME, Waikar SS, MacMahon B, Whelton S, Ballew SH, Coresh J: Performance and limitations of administrative data in the identification of AKI. Clin J AmSoc Nephrol 9: 682–689, 2014
27. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C: High serum uric acid and increased risk of type 2 diabetes: A systemic review and metaanalysis of prospective cohort studies. PLoS ONE 8: e56864, 2013
28. Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45: 28–33, 2005
29. Gagliardi AC, Miname MH, Santos RD: Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 202: 11–17, 2009
30. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA: Limits to causal inference based on Mendelian randomization: A comparison with randomized controlled trials. Am J Epidemiol 163: 397–403, 2006
31. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31, 2007
32. Palmer TM, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Davey Smith G, Lawlor DA, Timpson NJ: Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of twolarge cohorts. BMJ 347: f4262, 2013
33. Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Illig T, Hengstenberg C: Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE 4: e7729, 2009
34. McKeigue PM, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, Wright AF, Wilson JF: Bayesian methods for instrumental variable analysis with genetic instruments (‘Mendelian randomization’): Example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol 39: 907–918, 2010
35. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101–1106, 2001
36. Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M: Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NFkappaB. Am J Physiol Renal Physiol 292: F373–F381, 2007
37. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 89: 577–582, 1997
38. Sanchez-Lozada LG, Tapia E, Bautista-Garcıa P, Soto V, Avila- Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ: Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 294: F710–F718, 2008
39. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A; PERL Consortium: Uric acid lowering to prevent kidney function loss in diabetes: The Preventing Early Renal Function Loss (PERL) allopurinol study. Curr Diab Rep 13: 550–559, 2013
40. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW: Effects of uric acid-lowering therapy on renal outcomes: A systematic reviewand meta-analysis. Nephrol Dial Transplant 29: 406–413, 2014
41. Wang H, Jacobs DR Jr, Gaffo AL, Gross MD, Goff DC Jr, Carr JJ: Longitudinal association between serum urate and subclinical atherosclerosis: The Coronary Artery RiskDevelopment in Young Adults (CARDIA) study. J Intern Med 274: 594–609, 2013